TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Previously untreated stage IA, IB, IIA or IIB classical Hodgkin Lymphoma~* Non-bulky disease defined as less than 10 cm in maximal diameter~* Measurable disease greater than or equal to 1.5 cm~* ECOG performance status of 0 or 2~* Willing to use 2 effective forms of birth control~Exclusion Criteria:~* No prior chemotherapy or radiotherapy for Hodgkin lymphoma~* Not receiving any other investigational agents~* No history of allergic reactions attributed to compounds of similar chemical or biologic composition to Adriamycin, Vinblastine, Dacarbazine or brentuximab~* No pre-existing grade 3 or greater neuropathy~* No uncontrolled intercurrent illness~* Not pregnant or breastfeeding~* No history of a different malignancy unless disease free for at least one year

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): Brentuximab Vedotin in combination with Adriamycin, Vinblastine and Dacarbazine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reduction in YEllow Plaque by Aggressive Lipid LOWering Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient \> 18 years of age and willing to participate~* Stable patients who will undergo cardiac catheterization and PCI (intent to stent)~* Patient is willing to go on a cholesterol lowering medication for the duration of the study and willing to change statin therapy to the randomized statin therapy regardless of previous statin therapy and dose (e.g. Atorvastatin 80 mg) Patients that are screened for this study and are receiving another Statin such as Pravachol will be required to be willing to change their therapy to Rosuvastatin as per is randomization. If patients are receiving another statin, such as pravachol, or any other agent, and are at appropriate Lipid levels, they will be permitted to continue this therapy (if randomized to the standard therapy arm). There are a virtually unlimited number of possible scenarios for potential combination of all Lipid lowering agents at the time of enrollment that patients may be taking.~* Signed written Informed Consent~* Women of childbearing potential must agree to be on an acceptable method of birth control/contraceptive such as barrier method (condoms/diaphragm); hormonal contraceptives (birth control pills, implants (Norplant) or injections (Depo-Provera)); Intrauterine Device; or abstinence (no sexual activity).~* Fluency in English and/or Spanish~Exclusion Criteria:~* Patients who have acute myocardial infarction (Q wave or non-Q wave with CK-MB \> 5 times above the upper normal (31.5 ng/ml) within 72 hours)~* Patients who are in cardiogenic shock~* Patients with left main disease or restenotic lesions~* Patients with elevated CK-MB (\> 6.5 ng/ml) or Tnl (\> 0.5ng/L) at baseline~* Patients with platelet count \< 100,000 cell/mm3~* Patients who have co-morbidity which reduces life expectancy to one year~* Patients who are currently participating in another investigational drug/device study~* Patients with known hypersensitivity to HMG CO-A reductase therapy (statins)~* Patients with liver disease~* Patient with creatinine \> 2.0 mg/dL~* Pregnant women and women of childbearing potential who intend to have children during the duration of the trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- standard of care lipid therapy (Type: ACTIVE_COMPARATOR): standard-care lipid-lowering therapy: Zocor or Lipitor
- aggressive lipid therapy (Type: EXPERIMENTAL): aggressive lipid therapy: Crestor

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cancer Prevention Clinical Decision Support

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* meet above age criteria~* pcp practice at randomized clinic~Exclusion Criteria:~* current or past cancer diagnosis (excludes nonmelanoma skin cancer)~* hospice care or cancer chemotherapy~* Alzheimer's disease codes~* major cardiovascular event in 12 months prior to index date

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- CP-CDS (Type: EXPERIMENTAL): The CP-CDS group will receive a point of care clinical decision support tool called cancer prevention wizard (CP Wizard) that is integrated into the EHR. The CP Wizard provides evidenced- based recommendations to the provider and patient related to overdue cancer prevention screening services.
- CP-CDS + SDMT (Type: EXPERIMENTAL): The CP-CDS + SDMT group will receive a point of care clinical decision support tool called cancer prevention wizard (CP Wizard) that is integrated into the EHR. The CP Wizard provides evidenced- based recommendations to the provider and patient related to overdue cancer prevention screening services. The CP-CDS + SDMT arm also provides shared decision making tools to patient and provider at the time of the visit.
- Usual Care (Type: NO_INTERVENTION): The usual care group will have no access to the CP-CDS, or the CP-CDS + SDMT.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Thoracic Endoprosthesis for Treatment of Aneurysm of the Descending Thoracic Aortic

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:\>~1. Presence of DTA aneurysm deemed to warrant surgical repair \>~* Fusiform (≥50 mm), or \>~* Saccular (no diameter criteria)\> 2. Subject is \> 21 years of age\> 3. Proximal and distal landing zone length ≥ 2.0 cm \>~* Landing zones must be in native aorta\>~* Landing zone may include left subclavian artery, if necessary\> 4. All proximal and distal landing zone inner diameters are between 16-42 mm\>~* Diameter assessed by flow lumen and thrombus, if present; calcium excluded\> 5. Life expectancy \> 2 years\> 6. Able to tolerate thoracotomy \> 7. Male or infertile female\> 8. Able to comply with protocol requirements including following-up\> 9. Signed informed consent\>~Exclusion Criteria:\>~1. Differing proximal and distal neck diameters (aortic taper) outside the intended aortic diameter requirements (sizing guide) for a single endoprosthesis diameter and the inability to use devices of different diameters (in adherence to the sizing guide) to compensate for the taper\>~2. Tortuous or stenotic iliac and/or femoral arteries and inability to use a conduit for vascular access\>~3. Aneurysmal, dissected, heavily calcified, or heavily thrombosed landing zone(s)\>~4. Mycotic aneurysm\>~5. Hemodynamically unstable aneurysm rupture\>~6. Aortic dissection\>~7. Planned coverage of left carotid or celiac arteries with the CTAG Device\>~8. Planned concomitant surgical procedure (other than left subclavian transposition and wireless sac pressure monitoring), or major surgery within 30 days of treatment date\>~9. Known degenerative connective tissue disease, e.g. Marfan or Ehler-Danlos Syndrome\>~10. Known history of drug abuse\>~11. ASA risk classification = V (moribund patient not expected to live 24 hours with or without operation)\>~12. NYHA class IV \>~13. Participating in another investigational device or drug study within 1 year of treatment\>~14. Subject has known sensitivities or allergies to the device materials\>~15. Subject has a systemic infection and may be at increased risk of endovascular graft infection\>

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GORE CTAG Device (Type: EXPERIMENTAL): The primary endpoint of this study is freedom from a Major Device Event (MDE) through 1 month post-treatment in subjects treated with the GORE® Conformable TAG® Thoracic Endoprosthesis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 4 of 4)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy men or women between the ages of 18 and 45 years old~Exclusion Criteria:~* History (including family history) or symptoms of, or risk factors for bleeding~* History (including family history) of or risk factors for a hypercoagulable or thrombotic condition~* Absolute/relative contraindication to anticoagulation or treatment with specific anticoagulants~* History of major surgery, severe trauma or bone fracture within 3 months prior to dosing; or planned surgery within 1 month after dosing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Module 4 (600 mg bolus) (Type: EXPERIMENTAL): 600 mg PRT064445 given as a single IV bolus
- Module 4 (800 mg bolus + 480 mg infusion) 8mg/min (Type: EXPERIMENTAL): 1280 mg PRT064445: 800 mg IV at \~30 mg/min, followed by a continuous infusion of 480 mg (4 mg /min over 60 minutes)
- Module 4 (800 mg bolus) (Type: EXPERIMENTAL): 800 mg PRT064445 as a single IV bolus
- Module 4 Placebo (Type: PLACEBO_COMPARATOR): Placebo administered intravenously (IV) as a bolus or a bolus followed by continuous infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed informed consent and ability to comply with protocol requirements.~2. Documented diagnosis of AML according to World Health Organization WHO) classification~3. Adequate organ function as defined by the following laboratory values:~   1. Creatinine clearance \> 30 mL/min~  2. Total serum bilirubin \< 1.5 × ULN~  3. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \< 3 × ULN~4. Age ≥18 years~5. At least one TP53 mutation~6. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2~7. Projected life expectancy of ≥ 12 weeks.~8. Negative serum or urine pregnancy test~9. Females of childbearing potential and males with female partners of childbearing potential must be willing to use an effective form of contraception~Exclusion Criteria:~1. Prior treatment for TP53-mutant AML (\*dependent upon treatment arm assigned).~2. Known history of HIV or active hepatitis B or active hepatitis C infection.~3. Any of the following cardiac abnormalities:~   1. Myocardial infarction within six months prior to registration;~  2. New York Heart Association Class III or IV heart failure or known left ventricular ejection fraction (LVEF) \< 40%;~  3. A history of familial long QT syndrome;~  4. Symptomatic atrial or ventricular arrhythmias~  5. QTcF ≥ 470 msec, unless due to underlying bundle branch block and/or pacemaker and with approval of the medical monitor.~4. Concomitant malignancies for which patients are receiving active therapy~5. Known active CNS involvement from AML.~6. Malabsorption syndrome~7. Pregnancy or lactation.~8. Active uncontrolled systemic infection (viral, bacterial or fungal).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- APR-246 (Type: EXPERIMENTAL): APR-246 4.5 g/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open Label Safety Study of Enteric-Coated Spheroid Suspension in Infants Aged Less Than 12 Months With Presumed Gastroesophageal Reflux Disease (GERD)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Successful completion of the 3001B3-331 study (NCT00362609) or 3001B3-333 study (NCT00259012) Study.~Exclusion Criteria:~* Patients requiring chronic use of warfarin, carbamepazine, or phenytoin.

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 12 Months
- Healthy Volunteers: f

Study Arms:
- Low dose (Type: ACTIVE_COMPARATOR): None
- High dose (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Memantine for Prevention of Cognitive Decline in Patients With Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Able to provide informed consent~* At least 18 years of age~* Able to speak English~* Diagnosed with breast cancer, Stages I-III~* Scheduled for adjuvant or neoadjuvant chemotherapy~Exclusion Criteria:~* A history of adverse reaction to memantine~* Another cancer diagnosis with an estimated survival of less than five years~* Previous chemotherapy exposure~* Severe cognitive impairment, defined as Blessed Orientation Memory Concentration Test (BOMC) ≥ 11.~* Pregnancy, confirmed by a negative pregnancy test within 30 days of study enrollment, or breastfeeding~* Current alcohol or drug abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Memantine (Type: EXPERIMENTAL): Subjects receive memantin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dexamethasone-induced Hiccup in Chemotherapy Patients Treated by Methylprednisolone Rotation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* all solid cancer patients on chemotherapy~* age \>18 years~* received dexamethasone as an antiemetic~Exclusion Criteria:~* brain metastases~* hiccups before dexamethasone administration~* uncontrolled diabetes mellitus~* uncontrolled esophagitis or peptic ulcer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Methylprednisolone (Type: EXPERIMENTAL): Dexamethasone was replaced with methylprednisolone as an antiemetic.
- Dexamethasone (Type: ACTIVE_COMPARATOR): Dexamethasone was re-administered in the cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Examination of Psychological Tools and Tracking in an Online Intervention for Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Weight: Body Mass Index of 25-45 kg/m2 or greater.~* Current HbA1c of 6.5% or higher~* Regular access to the internet~Exclusion Criteria:~* Taking glucose lowering medications other than metformin~* Being pregnant or breastfeeding~* Currently undergoing cancer treatments~* Active use of a weight loss program or medications~* Self-reported impaired renal or hepatic function~* Self-reported untreated thyroid condition~* Vegetarian or vegan~* Weight loss surgery within the past year~* Medical concerns that prevent participants from following the assigned protocol

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Positive Affect, Mindfulness, Tracking (Type: EXPERIMENTAL): Participants will receive information about positive affect and mindfulness, in addition to being asked to actively track what they eat and receiving the core program
- Mindfulness, Tracking (Type: EXPERIMENTAL): Participants will receive information about mindfulness, be asked to actively track what they eat, and receive the core program.
- Positive Affect, Tracking (Type: EXPERIMENTAL): Participants will receive information about positive affect, be asked to actively track what they eat, and receive the core program.
- Tracking (Type: EXPERIMENTAL): Participants will be asked to actively track what they eat in addition to receiving the core program.
- Positive Affect, Mindfulness (Type: EXPERIMENTAL): Participants will receive information about positive affect and mindfulness in addition to the core program.
- Positive Affect (Type: EXPERIMENTAL): Participants will receive information about positive affect in addition to the core program.
- Mindfulness (Type: EXPERIMENTAL): Participants will receive information about mindfulness in addition to the core program.
- No Extras (Type: EXPERIMENTAL): Participants will receive the core program.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study of CDP870/Certolizumab Pegol in Patients With Active Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Inclusion Criteria:~* Patients who are diagnosed with Crohn's disease (according to the Crohn's disease diagnostic criteria developed by the research group on intractable inflammatory bowel disorders \[Shimoyama group, January 25, 2002\]) at least 24 weeks before the starting date of the observation period~* Patients with Crohn's Disease Activity Index (CDAI) score ranging from 220 to 450 inclusive during the observation period~* C-reactive protein (CRP) of 1 mg/dL or higher in the laboratory test performed at the start of the observation period~Exclusion Criteria:~* Stoma patient~* Patients with a history of severe hypersensitivity or anphylactic reaction to anti-TNF alpha antibody~* Patients who participated in a clinical study with CDP870~* Pregnant or lactating patients, patients of childbearing potential, or patients who will attempt pregnancy during the study period~* Patients who are judged inappropriate for enrollment by the principal investigator or subinvestigators~Exclusion Criteria:

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Certolizumab pegol 200 mg (Type: EXPERIMENTAL): Subjects received one subcutaneous (sc) injection of 200 mg CZP and one injection of Placebo to maintain the study blind on Weeks 0 (first dose), 2 and 4.
- Certolizumab pegol 400 mg (Type: EXPERIMENTAL): Subjects received two subcutaneous (sc) injections of 200 mg CZP on Weeks 0 (first dose), 2 and 4.
- Placebo (Type: PLACEBO_COMPARATOR): Subjects received two subcutaneous (sc) injections of Placebo on Weeks 0 (first dose), 2 and 4.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ongoing participation in a Phase 2 \[LX1606.1-202-CS (NCT00853047), LX1606.1-203-CS (NCT01104415)\] or Phase 3 \[LX1606.1-301-CS (NCT01677910), LX1606.1-303-CS (NCT02063659)\] study~* Patients of childbearing potential must agree to use an adequate method of contraception (defined as having a failure rate of \<1% per year) during the study and for 12 weeks after the Follow-up visit.~* Ability and willingness to provide written informed consent~Exclusion Criteria:~* Major protocol violations or tolerability concerns in a Phase 2 (eg, LX1606.1-202-CS, LX1606.1-203-CS) or Phase 3 (eg, LX1606.1-301-CS, LX1606.1-303-CS) study~* Positive pregnancy test~* Presence of any clinically significant findings at entry for medical history, laboratory values, or physical examination

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 250 mg Telotristat Etiprate (Type: EXPERIMENTAL): One telotristat etiprate (250 mg) tablet administered three times daily.
- 500 mg Telotristat Etiprate (Type: EXPERIMENTAL): Two telotristat etiprate (250 mg) tablets administered three times daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete